Abstract: To provide a water-soluble hyaluronic acid gel which does not contain a large amount of an organic solvent, wherein hyaluronic acid is not chemically modified. A water-soluble hyaluronic acid gel which contains hyaluronic acid, a polyhydric alcohol, an acid, and 0-10% by mass of a water-soluble organic solvent.

Abstract: A disinfestation article includes a base, external voids and internal voids formed in the base, pesticidal compound disposed in the external and internal voids. The pesticidal compound disposed in the external void being exposed to a surface of the base. The article may further comprise channels connecting one of the internal voids to one of the external voids. The pesticidal compound contains pesticidal particles selected from pyrethroid family or the like. Also claimed is a method of manufacturing which includes mixing pesticidal particles into a molten polymer material to form a mixture, injecting the mixture into a mold to form a molded part, and cooling the molded part to form said disinfestation article.

Abstract: A nanobubbler includes a porous ceramic material, a first inlet configured to inject a gas into the porous ceramic material, wherein the porous ceramic material is configured to emit nanobubbles into the chamber from the surface in response to the injection of the gas, a chamber positioned adjacent to a surface of the porous ceramic material, a second inlet configured to inject a liquid into the chamber so that the nanobubbles are dislodged from the surface of the porous ceramic material into the liquid, and an outlet configured to output from the chamber the liquid infused with the nanobubbles. The nanobubbles infused into the liquid have an average diameter of less than 500 nanometers.

Abstract: Provided is a bolus formed of a hydrogel, wherein the hydrogel includes water, a polymer, and a mineral, and wherein the bolus is applied to a patient who receives a radiation therapy.

Abstract: The present invention relates to a method for culturing bone marrow cells, in which bone marrow cells are applied to a porous polyimide film and cultured. Moreover, the present invention relates to a porous polyimide film for healing a bone injury site.

Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.

Abstract: Disclosed herein is a transdermal delivery system comprising methylphenidate or its salt as an active ingredient. Also provided are methods of delivering a therapeutically effective amount of methylphenidate to a subject for the treatment of a disease condition. The disease condition includes a neurological condition such as Attention Deficit Disorder (ADD) and/or Attention Deficit/Hyperactivity Disorder (ADHD). Kits including the transdermal delivery system and methods of making and using the transdermal delivery system are also provided.

Abstract: The present invention relates to improved formulations of Levosimendan for pharmaceutical use, and particularly for intravenous administration as infusion or injection and of infusion concentrates. The present invention therefore relates to pharmaceutical compositions comprising Levosimendan, in which Levosimendan is present in a solubilized form. The formulations have therapeutically and commercial useful concentrations of Levosimendan. The solutions of the invention have enhanced ability at physiological pH (pH 7.4) and are particular useful as infusion or injection solutions or infusion concentrates. The composition according to the present invention can also be spray-dried or lyophilized to obtain a dried powder which is very stable and which powder forms the original solution after reconstitution in water or an aqueous solvent. Levosimendan or (?)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazi-nyl)phenyl]hydrazono]propanedinitrile is useful in the treatment of congestive heart failure.

Abstract: The present invention relates to a method for culturing bone marrow cells, in which bone marrow cells are applied to a porous polyimide film and cultured. Moreover, the present invention relates to a porous polyimide film for healing a bone injury site.

Abstract: Disclosed herein are pharmaceutical compositions comprising Tadalafil, or a salt, or derivatives thereof and pharmaceutical excipients, processes for the preparation thereof, and pharmaceutical compositions containing them. The pharmaceutical compositions have improved physicochemical properties that provide faster onset of action for the treatment of erectile dysfunction.

Abstract: The present invention provides Glatiramer acetate compositions in a non-gelling matrix, formulated for sublingual delivery.

Abstract: Pharmaceutical compositions comprising at least one active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, at least one hydrophilic plastomer, at least one hydrophilic elastomer, and at least one deliquescent plasticizer, wherein the pharmaceutical compositions provide extended release of the API and have abuse deterrent properties. Methods for preparing the pharmaceutical compositions in which the components of the composition are humidified such that the deliquescent plasticizer deliquesces, thereby plasticizing the hydrophilic polymers.

Abstract: The present invention relates to a pharmaceutical composition, particularly a modified release tablet composition comprising mirabegron or a pharmaceutically acceptable salt thereof and to a process for preparing such a composition.

Abstract: The present disclosure disclosed a microsphere-producing process involving three integrated unit operations, 1) microspheres formation; 2) microsphere quality control; 3) post formation microsphere treatment. The first unit operation, i.e. unit operation 1) is integrated with four essential functions: forcing the particle forming materials to pass through a porous membrane to form embryonic micropsheres; enforcing the embryonic microspheres to detach the porous membrane; solidifying the embryonic microspheres; collecting and outputting the solidified microspheres. The quality control unit operation consists discrimination and ejection of oversized microspheres. The post treatment unit operation is integrated with two essential functions, smoothing the microsphere surfaces and reducing organic solvents trapped inside of microsphere matrix.

Abstract: A method and a composite material used for free forming a bone substitute are provided. The composite material comprises a support cloth, and a partially hardened bone paste coated on the support cloth. The bone paste contains a mixture of calcium sulfate and calcium phosphate in a weight ratio of 1:1 to 1:4. The bone substitute can be made by laminating the composite material either on a bone model or not.

Abstract: Compositions and methods of making and using of microparticle compositions that provide faster flow or improved injectability through smaller or small-diameter needles have been developed. Notably, the microparticle compositions can be successfully delivered or administered through smaller-diameter needles than other microparticle compositions prepared from biocompatible or biodegradable polymers including, for example, poly(lactide), poly(lactide-co-glycolide), polycaprolactone, or poly-3-hydroxybutyrate. The microparticle compositions can exhibit a higher solids loading for a given needle size and/or faster flow through needles than other microparticle compositions. Further, blending or mixing the polymer of the microparticle composition with other polymer formulations can enhance the injectability of the resulting formulation.

Abstract: The present invention provides a method for producing an active ingredient for a rivastigmine free base transdermal patch having preparing a rivastigmine free base; and adding an acidic substance to the rivastigmine free base and subjecting the acidic substance and the rivastigmine free base to a mixed reaction to form a mixture having a pH value from 6.0 to 8.5 as the active ingredient; and a rivastigmine free base transdermal patch having a drug layer comprising the active ingredient. The rivastigmine free base transdermal patch has a stable transdermal transmission time equal to or longer than 48 hours and equal to or less than 168 hours. The active ingredient produced by the method and the transdermal patch having the active ingredient allow effective and smooth release of rivastigmine free base and prolongs the release time to meet the clinical application needs.

Abstract: A formulation comprising a melt-processed solid dispersion product comprising an active agent, a pharmaceutically acceptable thermoplastic polymer of N-vinyl lactams, and a pharmaceutically acceptable polyvinyl alcohol-polyalkylene glycol graft copolymer. A method for producing said formulation.

Abstract: The present invention is directed to combination sunscreen and insect repellant compositions. The combination sunscreen and insect repellant compositions contain (i) diethyl toluamide (or N,N-Diethyl-3-methylbenzamide or DEET), and (ii) one or more sunscreen components, with each sunscreen component being capable of absorbing ultraviolet light rays. The combination sunscreen and insect repellant compositions may contain additional composition components such as a polymeric binder system, and deionized water. The present invention is also directed to methods of making and using combination sunscreen and insect repellant compositions.

Abstract: A system for the protection against degradation during pelleting of one or more physiologically or pharmacologically active substances, comprising compositions in the form of micro particles or granules, particularly for use in the zootechnical and/or veterinary field. The micro particles include a core which contains one or more substances having a pharmacological action, food supplements or diagnostic media, said one or more substances being characterized by the presence, within their chemical structure, of a basic functional group, specifically including an amine functional group. The core comprises also one or more carboxylic acids and/or their salts and eventually one or more excipients. Said core is coated by an outer layer of fats or waxes, and preferably by a mixture of glyceride of fatty acids.